Overview

Dexmedetomidine as a Rapid Bolus in Children for Emergence Agitation

Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
To Determine The Efficacy of a Rapid Bolus Injection of Dexmedetomidine on the Incidence of Emergence Agitation in Anesthetized Children and the Cardiovascular Profile of a Rapid Bolus Injection of Dexmedetomidine.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital of Pittsburgh
Peter Davis
Collaborators:
Hospira, Inc.
Hospira, now a wholly owned subsidiary of Pfizer
Treatments:
Dexmedetomidine